Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Immunotherapy-based combinations have rapidly become the dominant first-line treatment for advanced hepatocellular carcinoma ...

Sequential BCL2 inhibitor therapy shows initial responses but lacks durability, especially in patients exposed to both BTKi ...

Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and ...

Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus on ...

An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

Study shows treating vascular anomalies with mitogen‑activated protein kinase inhibitors results in high rates of cutaneous ...

The biotech will now take atebimetinib to mid- and late-stage trials in NSCLC and pancreatic cancer, respectively.

The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...